Company research
POINT Biopharma Global Inc.
CIK 1811764Updated Sep 27, 2026
Securities
Historical securities (2)
PNT · NASDAQ · equity · closed Dec 26, 2023RACA · NASDAQ · equity · closed Jul 1, 2021Name history
Therapeutics Acquisition Corp. · through Jun 30, 2021
PNT price & chart
Historical security
This listing closed Dec 26, 2023. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 578,322,736Source | 263,258,642Source | 136,907,267Source |
| Property, Plant and Equipment, NetUSD | 31,380,576Source | 19,412,086Source | — |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 286,428,371Source | 238,815,991Source | — |
| Assets, CurrentUSD | 530,822,730Source | 243,846,556Source | 1,200,872Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,610,889Source | 5,030,565Source | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 91,368,943Source | 8,045,556Source | 4,867,188Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 10,565Source | 9,012Source | — |
| Additional Paid in CapitalUSD | 448,391,574Source | 314,488,782Source | 5,311,049Source |
| Retained Earnings (Accumulated Deficit)USD | 39,008,505Source | -59,284,708Source | -311,513Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -456,851Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | — | — | 5,000,009Source |
| Liabilities and EquityUSD | 578,322,736Source | 263,258,642Source | 136,907,267Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 79,738,440Source | 7,979,964Source | 117,688Source |
| Accounts Payable, CurrentUSD | 7,703,150Source | 1,738,470Source | 5,109Source |
| Deferred Income Tax Liabilities, NetUSD | 0Source | 65,592Source | — |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 19,094,454Source | 5,990,516Source | 112,579Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 65,592Source | — |
| Short-term InvestmentsUSD | 238,783,470Source | — | — |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 98,293,213Source | -45,902,481Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,545,601Source | 2,302,607Source | — |
| Deferred Income Tax Expense (Benefit)USD | -65,592Source | 65,592Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 183,518,622Source | -44,698,758Source | — |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -266,264,986Source | -8,802,182Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 12,766,522Source | 8,802,182Source | — |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 130,358,744Source | 281,770,182Source | — |
| Payments of Ordinary Dividends, Common StockUSD | 0Source | 0Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 47,612,380Source | 228,269,242Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 286,428,371Source | 238,815,991Source | 1,094,556Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 92,338Source | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 3,545,601Source | 2,302,607Source | — |
| Amortization of Debt Issuance CostsUSD | 0Source | 11,840Source | — |
| DepreciationUSD | 1,395,029Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -405,527Source | -73,153Source | — |
| General and Administrative ExpenseUSD | 19,006,876Source | 12,006,438Source | — |
| Income Tax Expense (Benefit)USD | 31,292,875Source | 305,658Source | — |
| Net Income (Loss) Attributable to ParentUSD | 98,293,213Source | -45,902,481Source | — |
| Operating ExpensesUSD | 101,057,268Source | 45,511,830Source | — |
| Other Nonoperating Income (Expense)USD | 4,063,793Source | -84,993Source | — |
| Payments to Acquire InvestmentsUSD | 253,498,464Source | — | — |
| Proceeds from Issuance of Common StockUSD | 130,305,691Source | 264,882,682Source | — |
| Proceeds from Stock Options ExercisedUSD | 53,053Source | 450,000Source | — |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Total RevenueUSD | 226,579,563Source | — | — |
| Operating Income (Loss)USD | 125,522,295Source | -45,511,830Source | -13,114,805Source |
| Other Nonoperating Income (Expense)USD | 4,063,793Source | -84,993Source | -170,316Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 129,586,088Source | -45,596,823Source | -13,285,121Source |
| Income Tax Expense (Benefit)USD | 31,292,875Source | 305,658Source | 87,882Source |
| Net Income (Loss) Attributable to ParentUSD | 98,293,213Source | -45,902,481Source | -13,373,003Source |
| Earnings Per Share, BasicUSD per share | 1.04Source | -0.62Source | -0.34Source |
| Earnings Per Share, DilutedUSD per share | 1.02Source | -0.62Source | -0.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 94,601,214Source | 73,850,822Source | 38,875,643Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 96,034,506Source | 73,850,822Source | 38,875,643Source |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | 31,358,467Source | 240,066Source | 87,882Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -405,527Source | -73,153Source | -164,962Source |
| General and Administrative ExpenseUSD | 19,006,876Source | 12,006,438Source | 3,972,649Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 128,516,847Source | -46,225,053Source | -13,591,329Source |
| Interest Income (Expense), NetUSD | 4,469,320Source | -11,840Source | -5,354Source |
| Operating ExpensesUSD | 101,057,268Source | 45,511,830Source | 13,114,805Source |
| Research and Development ExpenseUSD | 82,050,392Source | 33,505,392Source | 9,142,156Source |